$NTLA
Intellia Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024093907 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $9.111M $6.957M
YoY Change -24.02% -48.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $30.50M $31.79M
YoY Change 3.74% 3.72%
% of Gross Profit
Research & Development $123.4M $114.2M
YoY Change 8.52% -0.93%
% of Gross Profit
Depreciation & Amortization $2.608M $2.599M
YoY Change 13.89% 19.77%
% of Gross Profit
Operating Expenses $123.4M $114.2M
YoY Change 8.52% -0.93%
Operating Profit -$144.8M -$139.0M
YoY Change 10.42% 5.07%
Interest Expense $9.058M -$7.932M
YoY Change 2.0% -191.67%
% of Operating Profit
Other Income/Expense, Net $9.058M -$7.932M
YoY Change 1.97% -191.67%
Pretax Income -$135.7M -$147.0M
YoY Change 11.04% 18.83%
Income Tax
% Of Pretax Income
Net Earnings -$135.7M -$147.0M
YoY Change 11.04% 18.83%
Net Earnings / Revenue -1489.54% -2112.62%
Basic Earnings Per Share -$1.34 -$1.52
Diluted Earnings Per Share -$1.34 -$1.52
COMMON SHARES
Basic Shares Outstanding 101.6M 96.48M
Diluted Shares Outstanding 101.0M 96.98M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $658.1M $691.1M
YoY Change -23.01% -23.9%
Cash & Equivalents $120.5M $130.8M
Short-Term Investments $537.6M $560.2M
Other Short-Term Assets $43.93M $53.81M
YoY Change 36.44% 103.19%
Inventory
Prepaid Expenses
Receivables $8.854M $12.33M
Other Receivables $0.00 $0.00
Total Short-Term Assets $710.9M $757.2M
YoY Change -20.44% -19.41%
LONG-TERM ASSETS
Property, Plant & Equipment $28.76M $30.27M
YoY Change -14.9% -8.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00
YoY Change -100.0% -100.0%
Other Assets $16.84M $49.84M
YoY Change -60.29% 21.46%
Total Long-Term Assets $462.4M $434.3M
YoY Change 32.18% 13.22%
TOTAL ASSETS
Total Short-Term Assets $710.9M $757.2M
Total Long-Term Assets $462.4M $434.3M
Total Assets $1.173B $1.192B
YoY Change -5.63% -9.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $13.15M $18.82M
YoY Change 269.97% 61.73%
Accrued Expenses $51.21M $45.13M
YoY Change -11.68% -8.9%
Deferred Revenue $22.16M $22.18M
YoY Change 65.99% 1.14%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $105.7M $105.1M
YoY Change 14.93% 5.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $105.1M $115.4M
YoY Change -7.85% -2.63%
Total Long-Term Liabilities $105.1M $115.4M
YoY Change -7.85% -2.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $105.7M $105.1M
Total Long-Term Liabilities $105.1M $115.4M
Total Liabilities $210.7M $220.5M
YoY Change 2.33% 0.97%
SHAREHOLDERS EQUITY
Retained Earnings -$2.049B -$1.913B
YoY Change 34.22% 36.24%
Common Stock $3.008B $2.885B
YoY Change 17.16% 14.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $962.6M $971.1M
YoY Change
Total Liabilities & Shareholders Equity $1.173B $1.192B
YoY Change -5.63% -9.95%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$135.7M -$147.0M
YoY Change 11.04% 18.83%
Depreciation, Depletion And Amortization $2.608M $2.599M
YoY Change 13.89% 19.77%
Cash From Operating Activities -$84.84M -$58.19M
YoY Change -16.32% -35.58%
INVESTING ACTIVITIES
Capital Expenditures $1.279M $1.012M
YoY Change -70.53% -76.47%
Acquisitions
YoY Change
Other Investing Activities -$6.430M -$23.18M
YoY Change -107.67% -23.35%
Cash From Investing Activities -$7.709M -$24.19M
YoY Change -109.7% -29.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 82.19M 41.25M
YoY Change 330.32% 1539.35%
NET CHANGE
Cash From Operating Activities -84.84M -58.19M
Cash From Investing Activities -7.709M -24.19M
Cash From Financing Activities 82.19M 41.25M
Net Change In Cash -10.35M -41.13M
YoY Change 272.45% -66.38%
FREE CASH FLOW
Cash From Operating Activities -$84.84M -$58.19M
Capital Expenditures $1.279M $1.012M
Free Cash Flow -$86.12M -$59.20M
YoY Change -18.54% -37.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001652130
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
CY2023Q2 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2024#LicenseAndServiceMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37766
dei Entity Registrant Name
EntityRegistrantName
INTELLIA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4785571
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Erie Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 130
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02139
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
285-6200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
NTLA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101579188
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130849000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
226748000
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
560219000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
685475000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12329000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36456000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
53814000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
49651000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
757211000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
998330000
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
248805000
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
99864000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
30273000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32760000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
105412000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
115375000
CY2024Q2 us-gaap Equity Method Investments
EquityMethodInvestments
0
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
11765000
CY2024Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
49835000
CY2023Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
42883000
CY2024Q2 us-gaap Assets
Assets
1191536000
CY2023Q4 us-gaap Assets
Assets
1300977000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
18816000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7452000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45127000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67017000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18963000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
18599000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22184000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
22140000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
105090000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
115208000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
28052000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38853000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
87332000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
96747000
CY2024Q2 us-gaap Liabilities
Liabilities
220474000
CY2023Q4 us-gaap Liabilities
Liabilities
250808000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
98289150
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
98289150
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
92997158
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
92997158
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
9000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2884997000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2710797000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1155000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2258000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1912790000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1658379000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
971062000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1050169000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1191536000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1300977000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6957000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13594000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
35892000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26200000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114207000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
115276000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
226054000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
212392000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31793000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30652000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62884000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
58100000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
146000000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
145928000
us-gaap Costs And Expenses
CostsAndExpenses
288938000
us-gaap Costs And Expenses
CostsAndExpenses
270492000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-139043000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-132334000
us-gaap Operating Income Loss
OperatingIncomeLoss
-253046000
us-gaap Operating Income Loss
OperatingIncomeLoss
-244292000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
12422000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
12653000
us-gaap Investment Income Interest
InvestmentIncomeInterest
25054000
us-gaap Investment Income Interest
InvestmentIncomeInterest
24633000
CY2024Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
-20354000
CY2023Q2 us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Gain Loss On Investments
GainLossOnInvestments
-26419000
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
CY2024Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
CY2023Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-4000000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7048000
CY2024Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
CY2023Q2 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-7932000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8653000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1365000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17485000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-146975000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-123681000
us-gaap Net Income Loss
NetIncomeLoss
-254411000
us-gaap Net Income Loss
NetIncomeLoss
-226807000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.4
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.58
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96975000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96975000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88185000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88185000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96238000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96238000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87979000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87979000
CY2024Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-208000
CY2023Q2 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1482000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-1029000
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
1507000
CY2024Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
292000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
0
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
2086000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-147183000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-124871000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-255440000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-223214000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
1050169000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1958000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
34176000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-821000
CY2024Q1 us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
2132000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-107436000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1036137000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1179000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1669000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
40861000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-208000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-146975000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
971062000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1235584000
CY2023Q1 ntla Contingent Consideration Paid To Rewrite Holders
ContingentConsiderationPaidToRewriteHolders
24126000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
755000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27255000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2989000
CY2023Q1 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
1794000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-103126000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1190843000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
465000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2051000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
36400000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1482000
CY2023Q2 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Investment Transferred From Available For Sale To Equity Method Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAociForInvestmentTransferredFromAvailableForSaleToEquityMethodTax
292000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-123681000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
1104888000
us-gaap Profit Loss
ProfitLoss
-254411000
us-gaap Profit Loss
ProfitLoss
-226807000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5111000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4220000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-15000
us-gaap Share Based Compensation
ShareBasedCompensation
75037000
us-gaap Share Based Compensation
ShareBasedCompensation
63655000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
9934000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
11667000
ntla Income Loss From Equity Method Investments Deferral Of Intra Entity Profit On Sales
IncomeLossFromEquityMethodInvestmentsDeferralOfIntraEntityProfitOnSales
-20967000
ntla Income Loss From Equity Method Investments Deferral Of Intra Entity Profit On Sales
IncomeLossFromEquityMethodInvestmentsDeferralOfIntraEntityProfitOnSales
5656000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-26419000
us-gaap Gain Loss On Investments
GainLossOnInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-7048000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
100000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-24128000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1289000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6239000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6078000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-9963000
ntla Increase Decrease In Operating Right Of Use Assets
IncreaseDecreaseInOperatingRightOfUseAssets
-9373000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1493000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
503000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10916000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6287000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-20555000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12525000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-10757000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-28919000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-9052000
ntla Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-8217000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-178848000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-199651000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3518000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8133000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
560368000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
625319000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
545597000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
476666000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18289000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-156786000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3137000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1220000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1669000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2051000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
101238000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4737000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-95899000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-351700000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
240353000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
535463000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144454000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183763000
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
130849000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
171806000
CY2024Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2023Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
11957000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144454000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
183763000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
631000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2998000
CY2024Q2 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
0
CY2023Q2 ntla Shares Issued For Rewrite Contingent Consideration
SharesIssuedForRewriteContingentConsideration
24126000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
810178000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
132000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1286000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
809024000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
785473000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
522000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
656000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
785339000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2023 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2024Q2 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2023Q4 ntla Available For Sales Securities Noncurrent Maturing Beyond Year Five
AvailableForSalesSecuritiesNoncurrentMaturingBeyondYearFive
0
CY2024Q2 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
21961000
CY2023Q4 ntla Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
27411000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14901000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26615000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3633000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2063000
CY2024Q2 ntla Accrued Construction Costs
AccruedConstructionCosts
2327000
CY2023Q4 ntla Accrued Construction Costs
AccruedConstructionCosts
6891000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2305000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4037000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
45127000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
67017000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
36456000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
11809000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
35936000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
12329000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
60993000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-10757000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
50236000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3768000
ntla Increase In Accounts Receivables
IncreaseInAccountsReceivables
9305000
ntla Decrease In Accounts Receivables
DecreaseInAccountsReceivables
8017000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5056000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
63771000
us-gaap Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Measure Of Progress
ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
0
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
-28919000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
34852000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10757000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
23273000
CY2024Q2 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
0
CY2024Q2 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
8804000
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures Fair Value Disclosure
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVenturesFairValueDisclosure
10000000
CY2024Q2 us-gaap Other Investments
OtherInvestments
24213000
CY2023Q4 us-gaap Other Investments
OtherInvestments
14760000
CY2024Q2 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2023Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
13605000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
3213000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
4518000
CY2024Q2 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
49835000
CY2023Q4 us-gaap Investments And Other Noncurrent Assets
InvestmentsAndOtherNoncurrentAssets
42883000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
40861000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36400000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
75037000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
63655000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4041753
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
50.4
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
3042554
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
34.2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1211234
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
51.67
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriod
501576
ntla Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Cancelled In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCancelledInPeriodWeightedAverageGrantDateFairValue
44.28
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
5371497
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
41.51
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.043
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.041
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.044
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.763
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.788
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.764
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.787
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5458999
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
50.38
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
35922000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
772191
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
190246
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.49
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
331773
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
77.99
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5709171
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
47.4
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M18D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15820000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4290920
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
45.38
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M3D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15812000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-146975000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-123681000
us-gaap Net Income Loss
NetIncomeLoss
-254411000
us-gaap Net Income Loss
NetIncomeLoss
-226807000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96975000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96975000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88185000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88185000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96238000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
96238000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
87979000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
87979000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.52
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.52
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.4
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.58
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11080000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11080000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9988000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9988000
CY2024Q2 ntla Rule10 B51 Arr Modified1 Flag
Rule10B51ArrModified1Flag
true

Files In Submission

Name View Source Status
0000950170-24-093907-index-headers.html Edgar Link pending
0000950170-24-093907-index.html Edgar Link pending
0000950170-24-093907.txt Edgar Link pending
0000950170-24-093907-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ntla-20240630.htm Edgar Link pending
ntla-20240630.xsd Edgar Link pending
ntla-ex10_1.htm Edgar Link pending
ntla-ex10_4.htm Edgar Link pending
ntla-ex31_1.htm Edgar Link pending
ntla-ex31_2.htm Edgar Link pending
ntla-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ntla-20240630_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending